Combining statins with interferon beta in multiple sclerosis: Think twice, it might not be all right

The Lancet Neurology

Volumn 10, Issue 8, 2011, Pages 672-673

  Zamvil, Scott S ^a,b   Steinman, Lawrence ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; HYPOCHOLESTEROLEMIC AGENT; INTERFERON RECEPTOR; PLACEBO; SIMVASTATIN; STAT1 PROTEIN; STAT2 PROTEIN;

BONE MARROW CELL; BRAIN DAMAGE; CLINICAL ASSESSMENT; DEMYELINATION; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LETTER; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SCIENTIFIC LITERATURE; TREATMENT CONTRAINDICATION;

ADMINISTRATION, ORAL; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERFERON; SIMVASTATIN;

EID: 79960375909     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70153-3     Document Type: Letter

References (10)

1. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
2. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008, 71:1390-1395.
3. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008, 3:e1928.
4. Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Multiple Sclerosis 2010, 16:848-854.
5. Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Multiple Sclerosis 2010, 16:450-454.
6. Sorensen PS, Lycke J, Eralinna J-P, et al. Simvastatin as add-on threrapy to interferon beta-1a for relapsing-remitting multiple sclerosis: a placebo-controlled randomised phase 4 study. Lancet Neurol 2011, for the SIMCOMBIN study investigators, published online July 11. 10.1016/S1474-4422(11)70144-2.
7. Stuve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006, 116:1037-1044.
8. Paintlia AS, Paintlia MK, Singh I, Singh AK Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 2006, 169:1012-1025.
9. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous sys tem autoimmune disease. Nat Med 2007, 13:935-943.
10. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nature Med 2010, 16:406-412.